Brief: Ovid Therapeutics Announces Phase 1 Results For Ov350
18/12/2025 13:33
Dec 18 (Reuters) - Ovid Therapeutics Inc OVID.O: OVID THERAPEUTICS INC - ANNOUNCES PHASE 1 RESULTS FOR OV350 OVID THERAPEUTICS INC - OV350 SHOWS GOOD SAFETY PROFILE SUPPORTING KCC2 PORTFOLIO ADVANCEMENT OVID THERAPEUTICS INC - NO TREATMENT-RELATED SAFETY FINDINGS OR SERIOUS ADVERSE EVENTS OVID THERAPEUTICS INC - OV4071 ON TRACK FOR REGULATORY SUBMISSION FOR PHASE 1/1B CLINICAL TRIAL IN Q1 2026 Source text: ID:nGNX929Fn3 Further company coverage: OVID.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors